Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival

Clinical and Experimental Immunology

Volumn 164, Issue 1, 2011, Pages 50-56

  Tsuchikawa, T ^a   Ikeda, H ^b   Cho, Y ^a   Miyamoto, M ^a   Shichinohe, T ^a   Hirano, S ^a   Kondo, S ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

HLA class I antigen expression; Oesophageal cancer; T cell infiltration

Indexed keywords

BETA 2 MICROGLOBULIN; CD57 ANTIGEN; HLA ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL INTERACTION; CELL SURVIVAL; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; DISEASE COURSE; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HEAVY CHAIN; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; TUMOR CELL; TUMOR VOLUME;

AGED; BETA 2-MICROGLOBULIN; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; ESOPHAGEAL NEOPLASMS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; TUMOR MICROENVIRONMENT;

EID: 79952504439     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04311.x     Document Type: Article

References (35)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349:2241-52.
2. Ando N, Ozawa S, Kitagawa Y etal. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000; 232:225-32.
3. Adham M, Bauleux J, Mornex F etal. Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus. Cancer 2000; 89:946-54.
4. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer. Lancet 2002; 359:1727-33.
5. Kelsen DP, Ginsberg R, Pajak TF etal. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339:1979-84.
6. Arnott SJ, Duncan W, Gignoux M etal. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys 1998; 41:579-83.
7. Goldminc M, Maddern G, Le Prise E etal. Oesophagectomy by transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg 1993; 80:367-70.
8. Garrio F, Cabrera T, Concha A etal. Natural history of HLA expression during tumor development. Immunol Today 1993; 14:491-99.
9. Seliger B, Maeurer MJ, Ferrone S. Antigen processing machinery breakdown and tumor growth. Immunol Today 2000; 21:455-64.
10. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 2002; 3:999-1005.
11. Marincola FM, Jaffee EM, Hicklin DJ etal. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74:181-273.
12. Jager MJ, Hurks HM, Levitskaya J etal. HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol 2002; 64:444-51.
13. Ogino T, Nobuyuki B, Hayashi T etal. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 2003; 9:4043-51.
14. Madjd Z, Spendlove I, Pinder SE etal. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005; 117:248-55.
15. Menon AG, Morreau H, Tollenaar RA etal. Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest 2002; 82:1725-33.
16. + T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 2003; 63:1555-59.
17. Coca S, Perez-Piqueras J, Martinez D etal. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 2003; 8:2320-28.
18. Hicklin DJ, Kageshita T, Ferrone S. Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. Tissue Antigens 1996; 48:38-46.
19. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986; 137:2299-306.
20. Lampson LA, Fisher CA, Whelan JP etal. Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 1983; 130:2471-8.
21. Ishigami S, Natsugoe S, Tokuda K etal. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000; 88:577-83.
22. Villegas FR, Coca S, Villarrubia VG etal. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002; 35:23-8.
23. Dunn GP, Bruce AT, Ikeda H etal. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-98.
24. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Ann Rev Immunol 2004; 22:329-60.
25. Cromme FV, van Bommel PFL, Walboomers JM etal. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 1994; 69:1176-81.
26. Vitale M, Rezzani R, Rodella L etal. HLA class I antigen and transporter associated with antigen processing (TAP1 andTAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 1998; 58:737-42.
27. Kageshita T, Ishihara T, Campoli M etal. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 2005; 65:419-28.
28. So T, Takenoyama M, Mizukami M etal. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 2005; 65:5945-52.
29. Feris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer. Immunol Res 2005; 33:113-33.
30. Ogino T, Shigyo H, Ishii H etal. HLA class I antigen down-regulation in primary lalyngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 2006; 66:9281-9.
31. Ryschich E, Notzel T, Hinz U etal. Control of T cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res 2005; 10:498-504.
32. Kooi S, Zhang HZ, Patenia R etal. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol 1996; 174:116-28.
33. Sadanaga N, Kuwano H, Watanabe M etal. Local immune response to tumor invasion in esophageal squamous cell carcinoma. The expression of human leukocyte antigen-DR and lymphocyte infiltration. Cancer 1994; 74:586-91.
34. Bird-Lieberman EL, Fittzgerald RC. Early diagnosis of oesophageal cancer. Br J Cancer 2009; 101:1-6.
35. Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 2008; 27:5869-85.